Apple said it plans to appeal the verdict, which could delay Masimo’s collection of the damages by as much as two years, one analyst said.
Jury orders Apple to pay Masimo $634M in patent fight Read More »
The projects, which include technology upgrades and expanded capacity initiatives, are designed to meet growing demand for services in the region.
Competing with companies including Stryker and J&J, Zimmer has moved to strengthen its position by developing an updated robot.
Zimmer wins FDA clearance for updated knee robot Read More »
The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and tariffs.
Resmed CEO Mick Farrell on new technologies, tariffs and AI Read More »
Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.
J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash Read More »
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy.
The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.
Lilly Bets More Than $2.6B For South Korea Biotech’s Bispecific Antibody Platform Read More »
Signs of Frustration Build Between Kennedy, Makary
Signs of Frustration Build Between Kennedy and FDA Commissioner Makary Read More »
Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and continues to evaluate its strategic alternatives.
Sensei Down to a Handful of Employees to Wrap Up Development Activities Read More »
Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line pancreatic cancer and third-line colorectal cancer.
Artios Pushes Cancer Pipeline Forward With $115M Series D Read More »
